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Abstracts / Biol Blood Marrow Transplant 20 (2014) S72eS90S9026 patients were treated with 27 SCTs at two centres
between 1999 and 2013. All patients had onset of symp-
toms before 7 years of age and were either TPN dependent
(n¼13) or had enteropathy refractory to at least 3 immu-
nosuppressive agents (n¼13) prior to transplant. Patients
with overt primary immunodeﬁciency were excluded. 8 of
26 patients had a conﬁrmed pathogenic mutation identi-
ﬁed (IPEX, XIAP, IL10, IL10Ra) and 18/26 remain gene-
tically undeﬁned. 11 patients (42%) had previously
undergone gut resections +/- defunctioning stoma for-
mation and 63% had suffered life threatening complica-
tions prior to transplant (sepsis, lymphoproliferative
disease, vasculitis).
22 SCTs were performed with fully HLA matched donors (8
family, 14 unrelated), and 5 with 9/10 mismatched donors.
With exception of 2 sibling donor grafts conditioned, all
patients received reduced toxicity conditioning, the ma-
jority with alemtuzumab 1mg/kg, ﬂudarabine 150mg/m2 +
either treosulphan 42g/m2 (n¼12) or melphalan 140mg/m2
(n¼10). Transplant related mortality was 23% (n¼6) from
GVHD, conditioning toxicity, viral infections and pulmonary
hypertension. One patient died from diabetic ketoacidosis
unrelated to SCT following a successful transplant. 96% of
patients engrafted, but one patient required a second graft
following rejection. The majority of patients (22/26) had full
donor chimerism at last follow-up, and the remaining 4
patients have stable mixed chimerism with 73-94% donor
chimerism within the lymphoid lineage. 8 patients (30%)
developed signiﬁcant aGVHD but the incidence of cGVHD
was low (n¼1, 4%).
At amedian follow-up of 51months,19 patients are alive,17 of
whom have had sustained improvement in their enteropathy.
8 surviving patients (89%) on TPN pre-transplant have now
discontinued and 14 (78%) are off all immunosuppression.
Our data demonstrate that reduced toxicity conditioned SCT
can cure the majority of patients with IEOC even in the
absence of a deﬁned genetic defect. We believe that given the
severity of this condition, SCT offers patients major improve-
ment in quality of life at an acceptable risk of toxicity and thatfurther studies of this approach in well-deﬁned patients are
warranted.SOLID TUMORS101
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Background: High-dose chemotherapy (HDCT) can achieve
durable remissions in 30-60% of GCT patients (pts) requiring
salvage treatment. This Phase I/II study investigated safety
and efﬁcacy of a novel high-dose regimen (TI-TIC) in this
population.
Methods: Pts age 18 with GCT and progression after 1
cisplatin-based regimen were eligible. TI-TIC consists of 1-
2 cycles of conventional-dose paclitaxel plus ifosfamide
(TI) q14-21 days followed by 3 cycles of high-dose TIC
with ASCT q21-28 days. TI dosing was constant. In Phase I,
high-dose TIC was administered in 1 of 5 cohorts (I: 6, 8 or
10g/m2; T: 200 or 250mg/m2; C: AUC¼21 or 24) using a
standard 3+3 dose escalation design to determine the
maximal tolerated dose (MTD). In Phase II, Simon’s 2-
stage optimal design was used to estimate the complete
response (CR) rate at MTD.
Results: Of 26 pts (25 male; median age 31; 21 non-
seminoma, 5 seminoma) enrolled, 23 received 1 cycle of
high-dose TIC. Primary sites included testis (n¼15), medi-
astinum (n¼6), other (5). In Phase I, 0/18 pts had dose-
limiting toxicity (DLT) during TIC cycle 1, making cohort 5 (T
250mg/m2, I 10g/m2, C AUC¼24) the MTD. Toxicities were
similar to those reportedwith TI-CE (Feldman JCO 2010) with
little variation across cohorts. However, 2/18 pts in Phase I (1
in cohort 4, 1 in cohort 5) developed grade 3 acute renal
insufﬁciency after TIC cycles 1 and 2 (cycle 3 not given). Both
later developed chronic renal insufﬁciency with 1 pt
requiring dialysis 10 months after TI-TIC. A third pt treated in
Phase II developed a similar acute and then chronic renal
insufﬁciency pattern with TIC cycles 1 and 2. In Phase II, 7/11
evaluable pts (64%, 90% one-sided CI 40%-100%) achieved a
CR,1 had a partial responsewith negativemarkers, and 3 had
incomplete responses. Although the CR rate was sufﬁcient to
move to the second Simon’s stage, renal toxicity led to pre-
mature trial closure.
Conclusions: Although there was preliminary evidence of
efﬁcacy, high dose TI-TIC was associated with acute and
chronic renal insufﬁciency. TI-CE remains the standard
high dose regimen for salvage treatment of GCT at MSKCC.
